Pathomechanisms of drug hepatotoxicity;Patomechanizmy hepatotoksycznego działania leków

Gastroenterologia Polska

Volumn 10, Issue 5, 2003, Pages 425-429

  Szela̧g, Adam ^a   Merwid La̧d, Anna ^a   Trocha, Malgorzata ^a   Skrzypiec, Monika ^a   Smereka, Adam ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Drugs; Hepatotoxicity; Liver

Indexed keywords

ALLOPURINOL; AMIODARONE; AMITRIPTYLINE; AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; BLEOMYCIN; CAPTOPRIL; CARBAMAZEPINE; CHLORPROMAZINE; CIMETIDINE; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; DRUG METABOLITE; FLUCLOXACILLIN; IBUPROFEN; IMIPRAMINE; ISONIAZID; LIVER ENZYME; NAPROXEN; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; RANITIDINE; SULFONAMIDE; SULINDAC; TETRACYCLINE; UNINDEXED DRUG;

BILE DUCT; BILE FLOW; BILE SECRETION; CHRONIC DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG RESPONSE; DRUG USE; DRUG WITHDRAWAL; EPIDEMIOLOGICAL DATA; FATTY LIVER; GRANULOMA; HUMAN; LIVER BLOOD VESSEL; LIVER CELL DAMAGE; LIVER FAILURE; LIVER FIBROSIS; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MEDICINE; PATHOPHYSIOLOGY; POLYPHARMACY; PREDICTION; PRESCRIPTION; REVIEW; RISK; SIDE EFFECT; SYMPTOMATOLOGY; TUMOR;

EID: 0345306725     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Kaplowitz N.: Drug metabolism and hepatotoxicity. [w:] Liver and biliary diseases, (red.) N. Kaplowitz. Williams and Wilkins, Baltimore, 1992, 82-97.
2. Whitehead M.W., Hawkes N.D., Hainsworth I., Kingham J.G.C.: A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut, 1999, 45, 129-133.
3. Dossing M., Andreasen P.B.: Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to Danish Board of Adverse Reactions to Drugs. Scand. J. Gastroenterol., 1982, 17, 205-211.
4. Friis, H., Andreasen P.B.: Drug-induced hepatic injury. An analysis of 1100 cases reported to the Danish Committee on Adverse Drug Reactions between 1978 and 1987. J. Intern. Med., 1992, 232, 133-138.
5. Zimmerman H.J., Maddrey W.C.: Toxic and drug-induced hepatitis. [w:] Diseases of the liver, (red.) L. Schiff, E.R. Schiff. Lippincott Company, Philadelphia, 1993, 707-783.
6. McNally P.R.: Polekowe choroby wa̧troby. [w:] Tajemnice hepatologii, (red.) P.R. McNally. Medical Press, Gdaṅsk, 1991, 94-105.
7. Benichou C.: Criteria of drug-induced liver disorders. Report of an International Consensus Meeting. J. Hepatol., 1990, 11, 272-276.
8. Aithal P.G., Day C.P.: The natural history of histologically proved drug induced liver disease. Gut, 1999, 44, 731-735.
9. , Gładysz A.: Polekowe i toksyczne uszkodzenia wa̧troby. [w:] Leczenie chorób wa̧troby, (red.) A. Gładysz, J. Juszczyk. Volumed, Wrocław, 1996, 222-230.
10. Angulo P., Keach J.C., Batts P., Kondor K.D.: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology, 1999, 30, 1356-1362.
11. Angulo P.: Nonalcoholic fatty liver disease. N. Engl. J. Med., 2002, 346, 1221-1231.
12. Gonciarz Z., Mazur W.: Polekowe uszkodzenia wa̧troby. [w:] Gastroenterologia i hepatologia kliniczna, (red.) S.J. Konturek. PZWL, Warszawa, 2001, 604-607.
13. Mitchell J.R., Jollow D.J., Potter W.Z., Gillette J.R., Brodie B.B.: Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther., 1973, 187, 211-217.
14. Lewis J.H., Zimmerman H.J.: Drug-induced liver disease. Med. Clin. North Am., 1989, 73, 775-792.
15. Miller R.R.: Hospital admissions due to adverse drug reactions: a report from Boston Collaborative Surveillance Program. Arch. Intern. Med., 1974, 134, 219-223.
16. Ellis G., Goldberg D.M., Spooner R.J., Ward A.M.: Serum enzyme tests in diseases of the liver and biliary tree. Am. J. Clin. Pathol., 1978, 70, 248-258.
17. Kaplan M.M.: Laboratory tests. [w:] Diseases of the liver, (red.) L. Schiff, J.B. Lippincott Company, Philadelphia, 1993, 108-144.
18. McIntyre N., Rosalki S.: Biochemical investigations in the management of liver disease. [w:] Oxford textbook of clinical hepatology, (red.) N. McIntyre, J.P. Benhamou, J. Bircher. Oxford University Press, Oxford, 1991, 293-309.
19. Schmidt E., Schmidt F.W.: Enzyme diagnosis in diseases of the liver and biliary system. [w:] Advances in clinical enzymology, (red.) E. Schmidt, F.W. Schmidt, I. Trautschold, R. Friedel. Karger, Basel, Tom 1, 1979, 239-292.
20. Bacon B., Faravash M.J., Janney C.G.: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology, 1994, 107, 1103-1106.
21. Cohen J.A., Kaplan M.M.: The SGOT/SGPT ratio: an indicator of alcoholic liver disease. Dig. Dis. Sci., 1979, 24, 835-838.
22. Diehl A.M., Goodman Z., Ishak H.G.: Alcohol-like liver disease in nonalcoholics. A clinical and histopathological comparison with alcohol-induced liver injury. Gastroenterology, 1989, 95, 10561060.
23. Lee R.G.: Nonalcoholic steatohepatitis. A study of 49 patients. Hum. Pathol., 1989, 20, 594-599.
24. Ludwig J., Viggiano R.T., McGill D.B.: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc., 1980, 55, 342-348.
25. Desmet V.: Vanishing bile duct syndrome in drug-induced liver disease. J. Hepatol., 1997, 26, supl. 1, 31-33.
26. Milewski B.: Toksyczne uszkodzenie wa̧troby. [w:] Zarys gastroenterologii i hepatologii, (red.) J. Dzieniszewski, Z. Knapik. PZWL, Warszawa, 1994, 347-353.
27. Batman P.A., Scheuer P.J.: Diabetic hepatitis preceding the onset of glucose intolerance. Histopathology, 1985, 9, 237-243.
28. Wanless I.R., Lentz J.S.: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology, 1990, 12, 1106-1110.
29. Olsson R., Wiholm B.E., Sand C., Zettergren L., Hultcrantz R., Myrhed M.: Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J. Hepatol., 1992, 15, 154-161.
30. Utili R., Boitnott J.K., Zimmerman H.G.: Dantrolene associated hepatic injury. Gastroenterology, 1977, 72, 610-616.
31. Ishak K.G., Irey N.S.: Hepatic injury associated with the phenothiazines. Arch. Pathol., 1972, 93, 284-304.
32. Maddrey W.C., Boitnott J.K.: Isoniazid hepatitis. Ann. Intern. Med., 1973, 79, 1-12.
33. Sharp J.R., Ishak K.G., Zimmerman H.J.: Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann. Intern. Med., 1980, 92, 14-19.
34. Toghill P.J., Smith P.G., Benton P., Brown R.C., Matthews H.L.: Methyldopa liver damage. BMJ, 1974, 3, 545-548.
35. Goldstein G.B., Lam K.C., Mistills S.P.: Drug-induced active chronic hepatitis. Am. J. Dig. Dis., 1973, 18, 177-184.
36. Seeff L.B.: Drug induced chronic liver disease, with emphasis on chronic active hepatitis. Semin. Liver Dis., 1981, 1, 104-115.
37. Lindberg J., Lindholm A., Lundin P., Iwarson S.: Trigger factors and HLA analysis in chronic active hepatitis. BMJ, 1975, 4, 77-79.
38. Farrell G.C.: Drug-induced chronic active hepatitis. [w:] Drug-induced liver disease, (red.) G.C. Farrell. Churchill Livingstone, Edinburgh, 1994, 413-430.
39. Graham D., Waller P., Kurz X.: A view from regulatory agencies. [w:] Pharmacoepidemiology, (red.) B.L. Strom. Wiley, Chichester, 2000, 91-108.
40. Lewis J.D., Strom B.L.: Balancing safety of dietary supplements with the free market. Ann. Intern. Med., 2002, 136, 616-618.
41. Kennedy D., Goldman S., Lillie R.: Spontaneous reporting in the United States. [w:] Pharmacoepidemiology, (red.) B.L. Strom. Wiley, Chichester, 2000, 151-174.